Abstract
The goals of tuberculosis control are to cure active disease, prevent relapse, reduce transmission and avert the emergence of drug resistance. However, since the 1960s, there have been few developments in available therapies. Currently available agents are complicated by numerous side-effects, drug interactions and the need for a long duration of therapy. Rifampicin-containing regimes lead to hepatic enzyme induction which can complicate or preclude the use of protease inhibitors and non-nucleoside reverse transcriptase inhibitors in patients infected with the human immunodeficiency virus. Furthermore, emerging drug resistance has complicated management for many patients and clinicians. Therefore, new chemotherapeutic agents are urgently needed. Existing antimicrobials are emerging as potent antituberculous agents. Recent studies have demonstrated the antituberculous activity of newer fluoroquinolones including levofloxacin, moxifloxacin, and gatifloxacin. Their use as first line antituberculous agents is currently under investigation. Furthermore, the oxazolidinones linezolid and PNU-100480 have been shown to have antituberculous activity in addition to their antibacterial effects. Several other agents are currently being developed for the treatment of tuberculosis. These agents include diarylquinolones (R207910), nitroimidazopyrans (PA-824, OPC-67683), ethambutol analogues (SQ109), cerulenin, trans-cinnamic acid, macrolides, pyrroles (LL3858), long-acting rifamycins and inhaled interferon-gamma. Furthermore, vaccines are being explored for pre-exposure and post-exposure use. This review will describe therapeutic developments in the management of tuberculosis, highlighting mechanisms of action of new pharmacological agents and their potential for clinical use.
Keywords: Tuberculosis, Drugs, Mycobacterium tuberculosis
Current Medicinal Chemistry
Title: Novel Agents in the Management of Mycobacterium Tuberculosis Disease
Volume: 14 Issue: 18
Author(s): P.J. Barry and T.M. O'Connor
Affiliation:
Keywords: Tuberculosis, Drugs, Mycobacterium tuberculosis
Abstract: The goals of tuberculosis control are to cure active disease, prevent relapse, reduce transmission and avert the emergence of drug resistance. However, since the 1960s, there have been few developments in available therapies. Currently available agents are complicated by numerous side-effects, drug interactions and the need for a long duration of therapy. Rifampicin-containing regimes lead to hepatic enzyme induction which can complicate or preclude the use of protease inhibitors and non-nucleoside reverse transcriptase inhibitors in patients infected with the human immunodeficiency virus. Furthermore, emerging drug resistance has complicated management for many patients and clinicians. Therefore, new chemotherapeutic agents are urgently needed. Existing antimicrobials are emerging as potent antituberculous agents. Recent studies have demonstrated the antituberculous activity of newer fluoroquinolones including levofloxacin, moxifloxacin, and gatifloxacin. Their use as first line antituberculous agents is currently under investigation. Furthermore, the oxazolidinones linezolid and PNU-100480 have been shown to have antituberculous activity in addition to their antibacterial effects. Several other agents are currently being developed for the treatment of tuberculosis. These agents include diarylquinolones (R207910), nitroimidazopyrans (PA-824, OPC-67683), ethambutol analogues (SQ109), cerulenin, trans-cinnamic acid, macrolides, pyrroles (LL3858), long-acting rifamycins and inhaled interferon-gamma. Furthermore, vaccines are being explored for pre-exposure and post-exposure use. This review will describe therapeutic developments in the management of tuberculosis, highlighting mechanisms of action of new pharmacological agents and their potential for clinical use.
Export Options
About this article
Cite this article as:
P.J. Barry and T.M. O'Connor , Novel Agents in the Management of Mycobacterium Tuberculosis Disease, Current Medicinal Chemistry 2007; 14 (18) . https://dx.doi.org/10.2174/092986707781368496
DOI https://dx.doi.org/10.2174/092986707781368496 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current Understanding on Biosynthesis of Microbial Polysaccharides
Current Topics in Medicinal Chemistry Insight View on Possible Role of Fluoroquinolones in Cancer Therapy
Current Topics in Medicinal Chemistry In vitro and In silico Analysis of β-lactam Derivatives as Antimycobacterial Agents
Letters in Drug Design & Discovery Screening of Few Epoxides as mt-MAPK Inhibitor Preventing Granuloma Formation to Serve as Tubercular Antidote
Letters in Drug Design & Discovery Vaccines and Vaccine Strategies Against HIV
Current Drug Targets Structural Genomics and Drug Discovery for Infectious Diseases
Infectious Disorders - Drug Targets The role of interleukin 35 in atherosclerosis
Current Pharmaceutical Design The Structure - Antituberculosis Activity Relationships Study in a Series of 5-(4-Aminophenyl)-4-Substituted-2,4-Dihydro-3h-1,2,4-Triazole-3-Thione Derivatives. A Combined Electronic-Topological and Neural Networks Approach
Medicinal Chemistry Cytokines as Immunomodulators in Tuberculosis Therapy
Recent Patents on Anti-Infective Drug Discovery Clinical and Regulatory Status of Silymarin
Applied Drug Research, Clinical Trials and Regulatory Affairs Evaluation of Arthritis in Hanseniase
Current Rheumatology Reviews Antimicrobial Potential of Benzamides and Derived Nanosystems for Controlling in vitro Biofilm Development on Medical Devices
Current Organic Chemistry Quinoxaline 1,4-di-N-Oxide and the Potential for Treating Tuberculosis
Infectious Disorders - Drug Targets Maternal Vitamin D Status and Development of Asthma and Allergy in Early Childhood
Mini-Reviews in Medicinal Chemistry Selected Pharmaceutical Excipient Prevent Isoniazid and Rifampicin Induced Hepatotoxicity
Current Drug Metabolism The Impact of Proteomic Advances on Bacterial Gene Annotation
Current Proteomics Purine and Pyrimidine Pathways as Targets in Plasmodium falciparum
Current Topics in Medicinal Chemistry Bacterial Siderophores and Their Potential Applications: A Review
Current Molecular Pharmacology Tofacitinib, an Oral Janus Kinase Inhibitor: Perspectives in Dermatology
Current Medicinal Chemistry Evolving Larger: Dosing Anti-Tuberculosis (TB) Drugs in an Obese World
Current Pharmaceutical Design